SEARCH

SEARCH BY CITATION

References

  • 1
    TerryWD, RosenbergSA (eds): Immunotherapy of Human Cancer. New York, Elsevier, 1982.
  • 2
    Oldham RK: Biological response modifiers. JNCI 70: 789796, 1983.
  • 3
    Rosenberg SA, Rapp HJ: Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 60: 419430, 1976.
  • 4
    Eilber FR, Morton DL, Holmes EC, et al: Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med 294: 237240, 1976.
  • 5
    Veronesi V, Adamus J, Aubert C, et al: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307: 913916, 1982.
  • 6
    Mastrangelo MJ, Berd D, Maguire HC Jr: Current condition and prognosis of tumor immunotherapy: A second opinion. Cancer Treat Rep 68: 207219, 1984.
  • 7
    Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495497, 1975.
  • 8
    Miller RA, Maloney DG, Warnke R, et al: Treatment of β-cell lymphoma with monoclonal anti-idiotype antibody. New Engl J Med 306: 517522, 1982.
  • 9
    Miller RA, Maloney DG, McKillop J, et al: In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 58: 7886, 1981.
  • 10
    Gutterman JU, Blumenschein GR, Alexanian R, et al: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93: 399406, 1980.
  • 11
    Merigan TC, Sikora K, Breeden JH, et al: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med 299: 14491453, 1978.
  • 12
    Horning SJ, Levine JF, Miller RA, et al: Clinical and immunological effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA 247: 17181722, 1982.
  • 13
    Grunberg SM, Kempf RA, Venturi CL, et al: Phase I study of recombinant β-interferon given by four-hour infusion. Cancer Res 47: 11741178, 1987.
  • 14
    Kurzrock R, Rosenblum MG, Sherwin SA, et al: Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res 45: 28662872, 1985.
  • 15
    Lotze MT, Matory YL, Ettinghausen SE, et al: In vivo administration of purified human interleukin 2: II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135: 28652875, 1985.
  • 16
    Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 316: 379385, 1987.
  • 17
    Lotze MT, Rosenberg SA: Protocol design for lymphokine testing in clinical studies of human cancer. Lymphokine Res 5: S177S182, 1986.
  • 18
    Merigan TC: Interferon—the first quarter century. JAMA 248: 25132516, 1982.
  • 19
    Lotze MT, Rosenberg SA: In vivo use of cytokines. Clin Immunol Newsletter 5: 116120, 1984.
  • 20
    Shu S, Chou T, Rosenberg SA: In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice. Cancer Res 47: 13541360, 1987.
  • 21
    Rosenberg SA, Eberlein TJ, Grimm EA, et al: Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: A new approach to the adoptive immunotherapy of cancer. Surgery 92: 328336, 1982.
  • 22
    Morton DL: Active immunotherapy against cancer: Present status. Semin Oncol 13: 180185, 1986.
  • 23
    Hoover HC Jr, Surdyke MG, Dangel RB, et al: Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55: 12361243, 1985.
  • 24
    Livingston PO, Albino AP, Chung TJ, et al: Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55: 713720, 1985.
  • 25
    O'Donnell RW, Marquis DM, Mudholkar GS, et al: In vivo enhancement of antitumor immunity by interleukin 2-rich lymphokines. Cancer Res 46: 32733278, 1986.
  • 26
    Koprowski H, Herlyn D, Lubeck M, et al: Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci USA 81: 216219, 1984.
  • 27
    Morales A, Eidinger D, Bruce AW: Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180183, 1976.
  • 28
    Lamon DL, Thor DE, Stogdill VD, et al: Bladder cancer immunotherapy. J Urol 128: 931935, 1982.
  • 29
    Ishida N, Hoshino J: A streptococcal preparation as a potent biological response modifier, OK-432. Tokyo, Excerpta Medica, 1985.
  • 30
    Izawa M-A, Ohno K, Amikura K, et al: Lentinan augments the production of interleukin 3 and colony stimulating factor(s) by T cells, in AokiJ, TsuburaE, UrushizakiI (eds): Manipulation of Host Defence Mechanism. Tokyo, Excerpta Medica, 1983, pp 5969.
  • 31
    Chirigos MA, Mastrangelo MJ: Immunorestoration by chemicals, in MihichE (ed): Immunological Approaches to Cancer Therapeutics. New York, John Wiley & Sons, Inc., 1982, pp 191239.
  • 32
    Bicker U: Aziridine dyes: Preclinical and clinical studies, in HershEM, ChirigosMA, MastrangeloMJ (eds): Progress in Cancer Research and Therapy. Vol 16, Augmenting Agents in Cancer Therapy. New York, Raven Press, 1981, pp 523537.
  • 33
    Symoens J, Rosenthal M, DeBrabander M, et al: Immunoregulation with levamisole, in ChedidL, MiescherPA, Mueller-EberhardHJ (eds): Immunostimulation. Berlin, Springer-Verlag, 1980, pp 195214.
  • 34
    Hadden JW, Giner-Sorolla A: Isoprinosine and NPT 15392: Modulators of lymphocyte and macrophage development and function, in HershEM, ChirigosMA, MastrangeloMJ (eds): Progress in Cancer Research and Therapy. Vol 16, Augmenting Agents in Cancer Therapy. New York, Raven Press, 1981, pp 497522.
  • 35
    Lotze MT: Treatment of immunologic disorders in AIDS, in DeVitaVT, HellmanS, RosenbergSA (eds): AIDS: Etiology, Diagnosis, Treatment, and Prevention. Philadelphia, JB Lippincott, 1985, pp 235264.
  • 36
    Hengst JCD, Kempf RA: Immunomodulation by cyclophosphamide, in MitchellMS, FaheyJL (eds): Clinics in Immunology and Allergy. Vol 4, Immune Suppression and Modulation. London, WB Saunders, 1984, pp 199216.
  • 37
    Ozer H: Effects of alkylating agents on immunoregulatory mechanisms, in MihichE, SakuraiY (eds): Biological Responses in Cancer. Vol 3, Immunomodulations by Anticancer Drugs. New York, Plenum Press, 1985, pp 95130.
  • 38
    Ehrke MJ, Mihich E: Adriamycin and other anthracyclines, in MitchellMS, FaheyJL (eds): Clinics in Immunology and Allergy. Vol 4, Immune Suppression and Modulation. London, WB Saunders, 1984, pp 259277.
  • 39
    Mastrangelo MJ, Berd D, Maguire H Jr: The immunoaugmenting effects of cancer chemotherapeutic agents. Semin Oncol 13: 186194, 1986.
  • 40
    Gutterman JU, Fein S, Quesada J, et al: Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 96: 549556, 1982.
  • 41
    Talpaz M, McCredie KB, Mavligit GM, et al: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogeneous leukemia. Blood 62: 689692, 1983.
  • 42
    Bergsagel DE, Haas RH, Messner HA: Interferon alfa-2b in the treatment of chronic granulocytic leukemia. Semin Oncol 13: 2934, 1986.
  • 43
    Quesada JR, Reuben J, Manning JT, et al: Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310: 1518, 1984.
  • 44
    Groopman JE: Therapeutic options in hairy-cell leukemia. Semin Oncol 12: 3034, 1985.
  • 45
    Volberding PA, Mitsuyasu R: Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma. Semin Oncol 12: 26, 1985.
  • 46
    Canellos GP: Interferon in the treatment of malignant lymphoma. Semin Oncol 12: 2529, 1985.
  • 47
    Foon KA, Roth MS, Bunn PA Jr: Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia. Semin Oncol 13: 3542, 1986.
  • 48
    Bunn PA Jr, Foon KA: Therapeutic options in advanced cutaneous T cell lymphomas: A role for interferon alpha-2a (Roferon-A). Semin Oncol 12: 1824, 1985.
  • 49
    Kirkwood JM, Ernstoff M: Melanoma: Therapeutic options with recombinant interferons. Semin Oncol 12: 712, 1985.
  • 50
    Kirkwood JM, Ernstoff M: Potential applications of the interferons in oncology: Lessons drawn from studies of human melanoma. Semin Oncol 13: 4856, 1986.
  • 51
    Cooper MR, Welander CE: Interferons in the treatment of multiple myeloma. Semin Oncol 13: 334340, 1986.
  • 52
    Cooper MR: Interferons in the treatment of multiple myeloma. Semin Oncol 13: 1320, 1986.
  • 53
    Quesada JR, Swanson DA, Trindade A, et al: Renal cell carcinoma: Antitumor effects of leukocyte interferon. Cancer Res 43: 940947, 1983.
  • 54
    Krown SE: Therapeutic options in renal-cell carcinoma. Semin Oncol 12: 1317, 1985.
  • 55
    Gedell DV, Kleid DG, Bolivar F, et al: Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA 76: 106110, 1979.
  • 56
    Howe PD, Marin ND, Hutchinson AS, et al: A fifteen month double blind crossover study of the efficacy and antigenicity of human and pork insulins. Diabetes Medicine 1: 9398, 1984.
  • 57
    Gutterman JU, Rosenblum MG, Rios A, et al: Pharmacokinetic study of partially pure gamma-interferon in cancer patients. Cancer Res 44: 41644171, 1984.
  • 57a
    Ernstoff MS, Trautman T, Davis CA, et al: A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol 5: 18041810, 1987.
  • 58
    Van DeWerl F, Vonbaecke J, de Geest H, et al: Coronary thrombolysis with recombinant single chain urolanase-type plasminogen activator in patients with acute myocardial infarction. Circulation 74: 10661070, 1986.
  • 59
    Verstraete M, Bernard R, Bory M, et al: Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1: 842847, 1985.
  • 60
    Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. New Engl J Med 316: 7378, 1987.
  • 61
    Asher A, Mulé JJ, Reichert CM, et al: Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963974, 1987.
  • 61a
    Groopman JE, Mitsuyasu RT, DeLeo MJ, et al: Effect of recombinant human granulocytemacrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 317: 593598, 1987.
  • 61b
    Guler H-P, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317: 137140, 1987.
  • 62
    Kurzrock R, Quesada JR, Talpaz M, et al: Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol 4: 11011109, 1985.
  • 63
    Nathan CF, Horowitz CR, De la Harpe J, et al: Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci USA 82: 86868690, 1985.
  • 64
    Kurzrock R, Rohde MF, Quesada JR, et al: Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J Exp Med 164: 10931101, 1986.
  • 65
    Pfizenmaier K, Scheurich P, Schlüter C, et al: Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J Immunol 138: 975980, 1987.
  • 66
    Bindon C, Czerniecki M, Ruell P, et al: Clearance rates and systemic effects of intravenously administered interleukin-2 (IL-2) containing preparations in human subjects. Br J Cancer 47: 123133, 1983.
  • 67
    Lotze MT, Frana LW, Sharrow SO, et al: In vivo administration of purified human interleukin 2: 1. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 134: 157166, 1985.
  • 68
    Lotze MT, Line BT, Mathisen DJ, et al: The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors. J Immunol 125: 14871493, 1980.
  • 69
    Lotze MT, Grimm EA, Mazumder A, et al: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor (TCGF). Cancer Res 41: 44204425, 1981.
  • 70
    Grimm EA, Robb RJ, Roth JA, et al: Lymphokine-activated killer cell phenomenon: III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 158: 13561361, 1983.
  • 71
    Perez P, Titus JA, Lotze MT, et al: Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J Immunol 137: 20692072, 1986.
  • 72
    Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 14851492, 1985.
  • 73
    Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immuno-therapy of cancer with tumor-infiltrating lymphocytes. Science 233: 13181321, 1986.
  • 74
    Eisenthal A, Lafreniere R, Lefor AT, et al: Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res 47: 27712776, 1987.
  • 75
    Cohen PJ, Lotze MT, Roberts JR, et al: The immunopathology of sequential tumor biopsies in patients treated with interleukin-2: Correlation of response with T-cell infiltration and HLA-DR expression. Amer J Pathol 129: 208216, 1987.
  • 76
    Cotran R, Lotze MT, Wiebke EA, et al: Endothelial activation during interleukin-2 (IL-2) immunotherapy: A possible mechanism for the vascular leak syndrome. J Immunol, 1988, in press.
  • 77
    Mulé JJ, Shu S, Schwarz SL, et al: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 255: 14871489, 1984.
  • 78
    Lafreniere R, Rosenberg SA: Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 45: 37353741, 1985.
  • 79
    Rosenberg SA, Mulé JJ, Spiess PJ, et al: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161: 11691188, 1985.
  • 80
    Mulé JJ, Yang JC, Lafreniere R, et al: Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 139: 285294, 1987.
  • 81
    Lotze MT, Custer MC, Sharrow SO, et al: In vivo administration of purified human interleukin-2 to patients with cancer: Development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following IL-2 administration. Cancer Res 47: 21882195, 1987.
  • 82
    Lotze MT, Matory YL, Rayner AA, et al: Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58: 194202, 1986.
  • 83
    Rosenberg SA, Lotze MT: Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 4: 681709, 1986.
  • 84
    Rosenberg SA, Lotze MT, Muul LM, et al: A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery 100: 262272, 1986.
  • 85
    Lotze MT, Rosenberg SA: Interleukin-2 as a pharmacologic reagent, in SmithK (ed): Lymphokines. New York, Academic Press, in press, 1987.
  • 86
    Cohen PJ, Lotze MT, Roberts JR, et al: The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T cell infiltration and HLA-DR expression. Amer J Pathol 129: 208216, 1987.
  • 87
    Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889897, 1987.
  • 88
    Lotze MT, Chang AE, Seipp CA, et al: High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: Responses, treatment-related morbidity, and histologic findings. JAMA 256: 31173124, 1986.
  • 89
    Munck A, Guyre PM, Holbrook NJ: Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 5: 2544, 1984.
  • 90
    Vetto JT, Papa MZ, Lotze MT, et al: Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroid. J Clin Oncol 5: 496503, 1987.
  • 91
    Nieman LK, Choate TM, Chrousos GP, et al: The progesterone antagonist RU 486: A potential new contraceptive agent. New Engl J Med 316: 187191, 1987.
  • 92
    Rosenberg SA, Terry WD: Passive immunotherapy of cancer in animals and man, in KleinG, WeinhouseS (eds): Advances in Cancer Research, vol 25. New York, Academic Press, 1977, pp 323388.
  • 93
    Order SE, Stillwagon GB, Klein JL, et al: Iodine 131 antiferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group study. J Clin Oncol 3: 15731582, 1985.
  • 94
    Tomita S, Lotze MT, Rosenberg SA: Clonal analysis of tumor infiltrating lymphocytes against human malignant melanoma. Fed Proc 46: 1195, 1987.
  • 95
    MitchellMS, OettgenHF (eds): Progress in Cancer Research and Therapy. Vol 21, Hybridomas in Cancer Diagnosis and Treatment. New York, Raven Press, 1982.
  • 96
    Schlom J: Basic principles and applications of monoclonal antibodies in the management of carcinomas: The Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 46: 32253238, 1986.
  • 97
    Haspel MV, McCabe RP, Pomato N, et al: Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 45: 39513961, 1985.
  • 98
    Liu AY, Robinson RR, Hellström KE, et al: Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci 84: 34393443, 1987.
  • 99
    Hellström I, Garrigues HJ, Cabasco L, et al: Studies of a high molecular weight human melanoma-associated antigen. J Immunol 130: 14671472, 1983.
  • 100
    Hellström I, Brankovan V, Hellström KE: Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci USA 82: 14991502, 1985.
  • 101
    Johnson VG, Schlom J, Paterson AJ, et al: Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 46: 850857, 1986.
  • 102
    Muraro R, Wunderlich D, Thor A, et al: Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 45: 57695780, 1985.
  • 103
    Fargion S, Carney D, Mulshine J, et al: Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res 46: 26332638, 1986.
  • 104
    Hellström I, Horn D, Linsley P, et al: Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res 46: 39173923, 1986.
  • 105
    Lotze MT, Carrasquillo JA, Weinstein JN, et al: Monoclonal antibody imaging of human melanoma: Radioimmunodetection by subcutaneous or systemic injection. Ann Surg 204: 223235, 1986.
  • 106
    Carrasquillo JA, Bunn PA Jr, Keenan AM, et al: Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N Engl J Med 315: 673680, 1986.
  • 107
    Engelstad BL, Spitler LE, Del Rio MJ, et al: Phase 1 immunolymphoscintigraphy with an In-111-labeled antimelanoma monoclonal antibody. Radiology 161: 419422, 1986.
  • 108
    Weinstein JN, Steller MA, Covell DG, et al: Monoclonal antitumor antibodies in the lymphatics. Cancer Treat Rep 68: 257264, 1984.
  • 109
    Scheinberg DA, Strand M, Gansow OA: Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science 215: 15111513, 1982.
  • 110
    Brown JP, Woodbury RG, Hart CE, et al: Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci USA 78: 539543, 1981.
  • 111
    Schulz G, Bumol TF, Reisfeld RA: Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 80: 54075411, 1983.
  • 112
    Schulz G, Staffileno LK, Reisfeld RA, et al: Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells. J Exp Med 161: 13151325, 1985.
  • 113
    Shiloni E, Eisenthal A, Sachs D, et al: Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol 138: 19921998, 1987.
  • 114
    Honsik CJ, Jung G, Reisfeld RA: Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 83: 78937897, 1986.
  • 115
    Karpovsky B, Titus JA, Stephany DA, et al: Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J Exp Med 160: 16861701, 1984.
  • 116
    Lotze MT, Roberts K, Custer MC, et al: Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: A possible approach to the immunotherapy of human tumors. J Surg Res 42: 580589, 1987.
  • 116a
    Titus JA, Perez P, Kaubisch A, et al: Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol 139: 31533158, 1987.
  • 117
    Redwood WR, Tom TD, Strand M: Specificity, efficacy, and toxicity of radioimmunotherapy in erythroleukemic mice. Cancer Res 44: 56815687, 1984.
  • 118
    Gilliland DG, Steplewski Z, Collier RJ, et al: Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA 77: 45394543, 1980.
  • 119
    Houston LL, Nowinski RC: Cell-specific cytotoxicity expressed by a conjugate of ricin and murine monoclonal antibody directed against thy 1.1 antigen. Cancer Res 41: 39133917, 1981.
  • 120
    Blythman HE, Casellas P, Gros O, et al: Immunotoxins: Hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumor cells. Nature 290: 145146, 1981.
  • 121
    Vitetta ES, Krolick KA, Uhr JW: Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Immunol Rev 62: 159183, 1982.
  • 122
    Thorpe PE, Ross WC: The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol Rev 62: 119158, 1982.
  • 123
    Spitler LE, del Rio M, Khentigan A, et al: Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res 47: 17171723, 1987.
  • 124
    Pimm MV, Jones JA, Price MR, et al: Tumour localization of monoclonal antibody against a rat mammary carcinoma and suppression of tumour growth with adriamycin-antibody conjugates. Cancer Immunol Immunother 12: 125134, 1982.
  • 125
    Baldwin RW, Embleton MJ, Pimm MV: Application of tumor-localizing 791T/36 monoclonal antibody in radioimmunodetection of experimental and human tumors and targeting cytotoxic drugs such as vindesine and methotrexate, in BossBD, LangmanR, TrowbridgeI, et al (eds): Monoclonal Antibodies and Cancer. Orlando, Fla, Academic Press, Inc, 1983, pp 265274.
  • 126
    Endo N, Kato Y, Takeda Y, et al: In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody. Cancer Res 47: 10761080, 1987.
  • 127
    Miller RA, Levy R: Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2: 226230, 1981.
  • 128
    Sears HF, Herlyn D, Steplewski E, et al: Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod 3: 138150, 1984.
  • 129
    Sindelar WF, Maher MM, Herlyn D, et al: Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: Preliminary results. Hybridoma 5: S125S132, 1986.
  • 130
    Goodman GE, Beaumier P, Hellström I, et al: Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 3: 340352, 1985.
  • 131
    Houghton AN, Mintzer D, Corden-Cardo C, et al: Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82: 12421246, 1985.
  • 131a
    Irie RF, Morton DL: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83: 86948698, 1986.
  • 131b
    Cheung N-KV, Lazarus H, Miraldi FD, et al: Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5: 14301440, 1987.
  • 132
    Skibber JM, Lotze MT, Muul LM, et al: Isolation of the human lymphokine activated killer characterization of the precursor and effector cell. Natural Immunology and Cell Growth Regulation, in press, 1987.
  • 133
    Roberts K, Lotze MT, Rosenberg SA: Separation and functional studies of the human lymphokine-activated killer cell. Cancer Res 47: 43664371, 1987.
  • 134
    Roberts K, Lotze MT, Rosenberg SA: Interleukin 2 (IL-2) promotes conjugate formation by purified lymphokine activated killer (LAK) precursors and T lymphocytes: Enumeration of cell conjugates by flow cytometry. J Biol Response Mod, in press.
  • 135
    Rosenberg SA: Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2, in DeVitaVTJr, HellmanS, RosenbergSA (eds): Important Advances in Oncology 1986. Philadelphia, JB Lippincott, 1986, pp 5591.
  • 136
    FeferA, GoldsteinAL (eds): Progress in cancer research and therapy. Vol 22, The Potential Role of T Cells in Cancer Therapy. New York, Raven Press, 1982.
  • 137
    Muul LM, Spiess PJ, Director EP, et al: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138: 989995, 1987.
  • 137a
    Topalian SL, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: A pilot study. Submitted for publication, 1988.
  • 138
    Lotze MT, Custer MC, Rosenberg SA: Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg 121: 13731379, 1986.
  • 139
    Papa MZ, Vetto JT, Shiloni E, et al: Synergistic effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Submitted, J Natl Cancer Inst, 1987.
  • 140
    Mulé JJ, Smith CA, Rosenberg SA: Interleukin-4 (B-cell stimulatory factor-1) can mediate the induction of LAK activity directed against fresh tumor cells. J Exp Med 166: 792797, 1987.
  • 140a
    Kawakami Y, Custer M, Rosenberg SA, et al: Human interleukin 4 (IL4) inhibits interleukin 2 (IL2) induction of human lymphokine activated killer (LAK) activity from peripheral blood and spleen cells. Fed Proc, in press, 1988.